The RAPID Consortium is a public-private partnership developing faster injectable drug manufacturing and packaging solutions that the U.S. Government and its allies can turn to in a national bio-emergency.
RAPID members may propose research projects that the Consortium may choose to submit to the U.S. Government through its Other Transaction Authority Agreement (OTAA) with the U.S. Department of Health and Human Services.
The RAPID Consortium seeks to bring together the best companies and organizations with U.S. government leaders focused on bio-emergency response. RAPID’s goal: enable surge production and faster delivery of injectable medicines and vaccines.
RAPID offers member organizations a wealth of opportunities for leadership, research, and growth, including:
RAPID embraces both established and new technologies in pharmaceutical manufacturing, packaging, and delivery – furthering their continued development so America and its allies can better respond to national emergencies.
For example, today with Government support, ApiJect (a founding member of RAPID) is advancing the use of Blow-Fill-Seal for injectable pharmaceuticals. The goal is to see how this established technology can be used in a new way – improving the speed and scale of packaging of injectable drugs for emergency response.